Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor <scp>MTPS9579A</scp> in asthma
The MTPS9579A dose tested in the phase 2a study was insufficient to inhibit tryptase in bronchial lining fluid, likely contributing to the observed lack of efficacy.
Authors
- Lindsay M. Henderson (ORCID: https://orcid.org/0000-0001-9444-4064)
- Sara B. Glickstein
- Ajit Dash (ORCID: https://orcid.org/0000-0003-4033-4614)
- Rebecca N. Bauer (ORCID: https://orcid.org/0000-0002-9530-1361)
- Victor Poon (ORCID: https://orcid.org/0000-0002-4215-2198)
- Prajna Banerjee (ORCID: https://orcid.org/0000-0002-8372-7648)
- Peter Bradding (ORCID: https://orcid.org/0000-0001-8403-0319)
- Gizette Sperinde
- Grażyna Pulka
- Steven T. Laing (ORCID: https://orcid.org/0000-0002-6079-3095)
- Dave Singh (ORCID: https://orcid.org/0000-0001-8918-7075)
- Horace Rhee
- Tracy Staton (ORCID: https://orcid.org/0000-0002-2718-9638)
- Parul Dayal (ORCID: https://orcid.org/0000-0003-0503-9337)
- Kenta J. Yoshida (ORCID: https://orcid.org/0000-0003-4967-3831)
- Nicholas S. Jones (ORCID: https://orcid.org/0000-0002-8318-0419)
- David F. Choy (ORCID: https://orcid.org/0000-0003-1351-6113)
- Chen Chen (ORCID: https://orcid.org/0000-0003-2104-534X)
- Kit Hong Wong
- Keyi Long
- Brian Leaker
- Alice Fong
Institutions
- University of Leicester (GB)
- Manchester University NHS Foundation Trust (GB)
- Centrum Medyczne iMed24 (PL)
- Respiratory Clinical Trials (GB)
- All-Med (PL)
Publication Details
- Journal
- Allergy
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1111/all.16309
- Citations
- 6
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.96
Funders
- National Institute for Health and Care Research
- Genentech